Categories: HealthcareNews

Health iPASS, a Sphere Company, enhances payment optionality for healthcare providers and their patients with Mastercard

NASHVILLE, Tenn., Aug. 27, 2024 /PRNewswire/ — Health iPASS, a Sphere company and leading provider of digital patient engagement solutions, announces it has enabled Mastercard’s account-to-account bill pay network, Remote Payment and Presentment Service (RPPS), to help power online healthcare bill pay in the U.S, offering more secure and frictionless digital payments choice for patients and providers.

Bill payments made via paper check continue to cause friction for healthcare providers, straining their cashflow and diverting their valuable time to manual, time-intensive payment reconciliation. Likewise, data from the Federal Reserve shows that while overall check volume is on the decline, billions still use paper checks for bill payments, representing an opportunity to optimize medical bill payments in the healthcare space.

With Health iPASS Bank Bill Pay solution, powered by Mastercard RPPS, Health iPASS’ tens of thousands of US healthcare providers can now offer their patients the option to pay their medical bill(s) digitally where they already manage and pay their other bills. This complements other electronic forms of payment, catering to a segment of payors preferring to streamline their bill payments through one entity. It also avoids the need to share sensitive account details with multiple parties and minimizes check fraud.

“We’re thrilled to partner with Mastercard to help our healthcare providers get paid quickly and electronically to avoid the hassle of paper checks,” said Curtis Bauer, CEO of Health iPASS. “A costly problem for our healthcare providers is the considerable volume of their patients’ payments via offline paper checks. Adding online bank bill pay as a payment option on Health iPASS healthcare providers’ invoices will help our healthcare providers convert these unwanted checks into faster, more secure digital payments.”

“Providing a streamlined payments experience, while offering patients optionality in how they pay, continue to be critical needs for healthcare providers,” said Joseph Zeltzer, SVP, Product Management, Mastercard, North America. “Mastercard RPPS enables healthcare providers to get paid digitally through bank bill pay, reducing physical checks and ultimately improving cashflow and efficiency. We’re delighted to partner with Health iPASS to take another step towards helping solve critical payments needs for the healthcare industry.”

To learn more about how Health iPASS can transform your patient experience and increase collections, visit Healthipass.com.

About Health iPASS

Health iPASS, a Sphere company, is an innovative provider of cloud-based patient engagement software. Health iPASS solutions enhance provider revenue collections and deliver a streamlined healthcare consumer experience from appointment to final payment. The Health iPASS software platform simplifies the check-in process and payment workflow prior to and at time-of-service. The technology also streamlines post service payment collection through an innovative, multi-channel, virtual software interface. Health iPASS is committed to delivering better check-ins for patients and better revenue for medical practices. To learn more, visit http://www.healthipass.com.

Media Contact:
Michelle Noteboom
Amendola Communications
mnoteboom@acmarketingpr.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/health-ipass-a-sphere-company-enhances-payment-optionality-for-healthcare-providers-and-their-patients-with-mastercard-302230808.html

SOURCE Health iPass, a Sphere company

Staff

Recent Posts

Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial

Media ReleaseCOPENHAGEN, Denmark; September 15, 2024 Treatment with rinatabart sesutecan (Rina-S) showed encouraging response rate…

6 hours ago

Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis

Trial investigating Cabometyx® (cabozantinib) in combination with atezolizumab demonstrated a positive trend towards improvement for…

6 hours ago

KFSHRC Leads as a Premier Destination for Medical Tourism and Innovative Care Solutions

RIYADH, Saudi Arabia, Sept. 15, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research…

6 hours ago

Precede Biosciences Presents New Data at ESMO 2024 Demonstrating Ability to Reveal Tumor PSMA Expression from a Simple Blood Test that is Highly Correlated with PSMA-PET Imaging

Prostate-specific membrane antigen (PSMA) is a leading target for next-generation prostate cancer therapies, with one…

6 hours ago

23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study

23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit in clear-cell renal-cell carcinoma, with one confirmed…

6 hours ago